the-seres-therapeutics-(nasdaq:mcrb)-share-price-has-soared-590%,-delighting-many-shareholders

The Seres Therapeutics (NASDAQ:MCRB) Share Price Has Soared 590%, Delighting Many Shareholders

View photos

NASDAQ:MCRB) has generated a beautiful 590% return in just a single year. And in the last month, the share price has gained -7.6%. This could be related to the recent financial results that were recently released – you could check the most recent data by reading our company report. Looking back further, the stock price is 89% higher than it was three years ago.” data-reactid=”28″ type=”text”>While stock picking isn’t easy, for those willing to persist and learn, it is possible to buy shares in great companies, and generate wonderful returns. When you find (and hold) a big winner, you can markedly improve your finances. For example, Seres Therapeutics, Inc. (NASDAQ:MCRB) has generated a beautiful 590% return in just a single year. And in the last month, the share price has gained -7.6%. This could be related to the recent financial results that were recently released – you could check the most recent data by reading our company report. Looking back further, the stock price is 89% higher than it was three years ago.

We love happy stories like this one. The company should be really proud of that performance!

Check out our latest analysis for Seres Therapeutics ” data-reactid=”30″ type=”text”> Check out our latest analysis for Seres Therapeutics

Because Seres Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn’t make profits, we’d generally expect to see good revenue growth. That’s because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last year Seres Therapeutics saw its revenue shrink by 27%. This is in stark contrast to the splendorous stock price, which has rocketed 590% since this time a year ago. There can be no doubt this kind of decoupling of revenue growth and share price growth is unusual to see in loss making companies. Typically, when we see this in a biotech stock, it’s because investors are getting excited about an impending drug development milestone, such as clinical trial results. While this gain looks like speculative buying to us, sometimes speculation pays off.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth

earn in the future (free profit forecasts).” data-reactid=”50″ type=”text”>We’re pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. So it makes a lot of sense to check out what analysts think Seres Therapeutics will earn in the future (free profit forecasts).

A Different Perspective

Seres Therapeutics is showing 3 warning signs in our investment analysis , you should know about…” data-reactid=”52″ type=”text”>It’s good to see that Seres Therapeutics has rewarded shareholders with a total shareholder return of 590% in the last twelve months. That certainly beats the loss of about 6.7% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. It’s always interesting to track share price performance over the longer term. But to understand Seres Therapeutics better, we need to consider many other factors. Even so, be aware that Seres Therapeutics is showing 3 warning signs in our investment analysis , you should know about…

list of growing companies that insiders are buying.” data-reactid=”53″ type=”text”>If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”55″ type=”text”>

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top